About This Webinar

Investigating complex PSA proteoforms with efficiency and consistency

Early detection of prostate cancer may lead to the overdiagnosis and overtreatment of patients as well as missing significant cancers. The current diagnostic approach uses elevated serum concentrations of prostate-specific antigen (PSA) as an indicator of risk. However, this test has been widely criticized as it shows poor specificity and sensitivity.



In order to improve early detection and diagnosis, several studies have investigated whether different PSA proteoforms are correlated to prostate cancer. Unfortunately, data processing of the various proteoforms of this intact protein represents an analytical bottleneck for the investigation of clinical cohorts.

In this webinar, Alan Moran, PHD researcher at the LUMC, will describe the application of a customized intact protein workflow for the analysis of intact PSA, exploring its N-glycome as well as other PSA proteoforms. As a result of using Byos® from Protein Metrics, an easier, faster, and more efficient data analysis and processing of clinically relevant PSA proteoforms is achieved.